AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04486443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
Study NCT02956473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib
Description: 1 x 30 mg tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanraplenib
Description: 1 x 30 mg tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 1 x 200 mg tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib
Description: 1 x 200 mg tablet administered orally once daily
Study NCT03610282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Subjects will received propofol for up to 100 minutes.
Study NCT03610282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Subjects will received propofol for up to 100 minutes.
Study NCT03266731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
Study NCT04046055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 2 mA
Description: Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Study NCT04046055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Study NCT04046055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation
Description: Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
Study NCT03041857 — intervention group
Intervention type: RADIATION
Intervention: Observational use of fluoroscopy
Study NCT00386386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion
Description: Above
Study NCT01492569 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture therapy
Description: Undergo TAPS at sham point
Study NCT01492569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01492569 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01492569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture therapy
Description: Undergo TAPS
Study NCT02678273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~.
Study NCT01253473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
Study NCT01253473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Description: Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
Study NCT01253473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium/albuterol
Description: Inhaled ipratropium/albuterol combination 2 puffs four times daily
Study NCT01253473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium/albuterol
Description: Inhaled ipratropium/albuterol combination 2 puffs four times daily
Study NCT01426438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Study NCT01426438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
Study NCT01426438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
Study NCT01784848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Description: Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
Study NCT01784848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical treatment
Description: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
Study NCT02956473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammography
Study NCT02956473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Study NCT02956473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard MRI
Study NCT04347109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non invasive epicardial mapping
Description: Non invasive mapping using Cardio Insight system is performed in all included patients.
Study NCT02494115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcutaneous drainage
Study NCT03134209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zipper surgical skin closure
Description: The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
Study NCT03134209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl + Dermabond
Description: conventional sutures and skin adhesive glue
Study NCT03134209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyester mesh + Dermabond
Description: conventional sutures and skin adhesive glue
Study NCT01827020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2 %
Description: 12 mL lidocaine 2% 1mg/kg
Study NCT01827020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus Lidocaine
Description: ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
Study NCT01827020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12 mL saline (0.9% isotonic solution)
Study NCT03001986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated EV71 vaccine (KMB-17 cells)
Description: Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
Study NCT04861701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static stretching exercise
Description: The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
Study NCT03014089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1325
Description: Escalating dose levels
Study NCT03014089 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01596023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe NIOV Ventilator
Description: Portable, non invasive open ventilation system
Study NCT02499237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
Study NCT03328949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVL Coronary Lithotripsy System
Description: The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
Study NCT01205750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: 450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
Study NCT02499237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
Study NCT03091257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Administered Orally once daily
Study NCT03056469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Completion of patient-reported outcome (PRO) questionnaires
Description: Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
Study NCT02445911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQ-791
Description: Capsules administered orally
Study NCT02445911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally
Study NCT02985944 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed in adult consecutive patients for different indications
Study NCT03257657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observation Group participants
Description: Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
Study NCT03257657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle group participants
Description: Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
Study NCT00141011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ancrod (Viprinex)
Description: 0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
Study NCT00141011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.6 mL/kg/hr
Study NCT01828060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jobelyn™
Description: Sorghum bicolor leaf sheath extract
Study NCT01828060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT02126891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tests
Description: Individual parameters of echocardiography and heart rate variability
Study NCT01657188 — intervention group
Intervention type: DEVICE
Intervention: Cheyne-Stokes respiration by adaptive servoventilation
Study NCT01163942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Yes/no addition of G-CSF
Study NCT01784848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical treatment
Description: Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
Study NCT03888586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigger Point Dry Needling Technique
Description: The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirabrutinib
Description: 1 x 40 mg tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: 1 x 40 mg tablet administered orally once daily
Study NCT03888586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Friction Massage Technique
Description: For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
Study NCT00271024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (drug)
Description: 50 mg q.d. for 13 weeks
Study NCT00271024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Naltrexone)
Description: Sugar pill manufactured to mimic Naltrexone tablet
Study NCT01837641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-IV
Description: Administered IV
Study NCT01837641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813-SC
Description: Administered SC
Study NCT01837641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-IV
Description: Administered IV
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: 1 x tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanraplenib placebo
Description: 1 x tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: 1 x tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib placebo
Description: 1 x tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib placebo
Description: 1 x tablet administered orally once daily
Study NCT03100942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirabrutinib placebo
Description: 1 x tablet administered orally once daily
Study NCT02709629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized and adaptive computerized cognitive training
Study NCT02709629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Study NCT04651920 — intervention group
Intervention type: GENETIC
Intervention: Evaluation of homologous recombination deficiency score
Description: Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
Study NCT04271072 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04674709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleander 4X - single
Description: Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
Study NCT04674709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleander 4X - single
Description: Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
Study NCT04674709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleander 4X - double
Description: Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
Study NCT04674709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleander 4X - double
Description: Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
Study NCT04674709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleander 4X - quadruple
Description: Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
Study NCT04674709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleander 4X - quadruple
Description: Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
Study NCT01163942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early retreatment with ATG
Description: Yes/no early retreatment with ATG
Study NCT03960736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESP block (Group A)
Description: US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
Study NCT03960736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA group (Group B)
Description: Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
Study NCT03599765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive routine therapy
Study NCT00630370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets, TID, orally, 58 days
Study NCT00630370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg ATI 7505
Description: 1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
Study NCT03599765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Receive LCT
Study NCT00712283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neramexane mesylate
Description: tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
Study NCT00712283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neramexane mesylate
Description: tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
Study NCT00864357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
Description: A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
Study NCT00864357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBONOX® tablets, single dose
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
Study NCT00630370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg ATI 7505
Description: 1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days